Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩4,625, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total loss to shareholders of 6.6% over the past three years. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩5,130, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Jun 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩6,650, the stock trades at a trailing P/E ratio of 47.7x. Average trailing P/E is 13x in the Personal Products industry in South Korea. Total returns to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • May 15
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩8,000, the stock trades at a trailing P/E ratio of 75.8x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 60% over the past three years. 공고 • Feb 27
GFC Life Science Co., Ltd, Annual General Meeting, Mar 26, 2026 GFC Life Science Co., Ltd, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 823, dongtansunhwan-daero, gyeonggi-do, hwaseong South Korea New Risk • Dec 31
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (₩74.2b market cap, or US$51.3m). 공고 • Jun 25
GFC Life Science Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 11.9952 billion. GFC Life Science Co., Ltd has completed a Follow-on Equity Offering in the amount of KRW 11.9952 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 196,000
Price\Range: KRW 15300
Discount Per Security: KRW 612
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 588,000
Price\Range: KRW 15300
Discount Per Security: KRW 612 New Risk • Jun 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Market cap is less than US$100m (₩113.1b market cap, or US$83.2m). New Risk • May 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩74.8b market cap, or US$53.7m). 공고 • Mar 06
GFC Life Science Co., Ltd, Annual General Meeting, Mar 26, 2025 GFC Life Science Co., Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 823, dongtansunhwan-daero, gyeonggi-do, hwaseong South Korea New Risk • Dec 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩42.6b market cap, or US$29.7m). New Risk • May 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (₩21.8b market cap, or US$15.9m). New Risk • Jul 24
New major risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩16.1b (US$12.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩16.1b market cap, or US$12.5m).